---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-016131"
form_type: "8-K"
ticker: "CRVO"
cik: "0001053691"
company_name: "CervoMed Inc."
filed_at: "2025-05-12T23:59:59+00:00"
generated_at: "2026-05-21T22:48:12.191186+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# CervoMed posts Q1 net loss $4.9M, secures $50M ATM facility; reports positive Phase 2b DLB results

## Summary
- Entered $50M at-the-market offering agreement with Leerink Partners; 3% commission on sales.
- Cash and marketable securities $35.2M at March 31, 2025, down from $38.9M at Dec 31, 2024; runway into mid-2026.
- Net loss $4.9M for Q1 2025 compared to $2.5M in Q1 2024, driven by higher R&D costs for neflamapimod.
- Sixteen-week extension data from RewinD-LB Phase 2b showed CDR-SB improvement (p<0.001 vs old capsules, p=0.003 vs placebo); Phase 3 planned in mid-2026.
- Initiating Phase 2a trials in primary progressive aphasia (mid-2025) and ischemic stroke recovery (recently started).

## SEC filing metadata
- accession: 0001437749-25-016131
- form_type: 8-K
- ticker: CRVO
- cik: 0001053691
- company_name: CervoMed Inc.
- filed_at: 2025-05-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1053691/000143774925016131/0001437749-25-016131-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1053691/000143774925016131/crvo20250509_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-016131
- JSON: https://secwatch.observer/filing/0001437749-25-016131.json
- Plain text: https://secwatch.observer/filing/0001437749-25-016131.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.